Viva Biotech Holdings (01873.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.8x

Market Cap

HKD 2.82B

MomentumView details →

1D Return

−2.20%

YTD Return

−25.83%

RSI (14)

44.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.8x

Market Cap

HKD 2.82B

RSI (14)

44.0

MomentumView details →

1D Return

−2.20%

YTD Return

−25.83%

ProfitabilityView details →

Gross Margin

35.98%

Net Margin

9.37%

EBITDA Margin

21.72%

ROE (TTM)

8.82%

ROA (TTM)

5.07%

Asset Turnover

0.53x

GrowthView details →

Revenue YoY

−15.46%

EPS YoY

+171.15%

FCF YoY

+24.58%

Revenue CAGR 3Y

−10.09%

EPS CAGR 3Y

+14.94%

EBITDA YoY

−5.71%

EarningsView details →

EPS (Actual)

HKD 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

1.28%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

1.52x

Quick Ratio

1.18x

Div Yield

—

Div Rate

—

Div Growth 1Y

−68.75%

Financials snapshotView financials →

Revenue (TTM)

3.73B

Net Income (TTM)

349.22M

Op. CF (TTM)

778.84M

Next earningsApr 1, 2027 →

Latest newsMore news →

Viva Biotech Holdings announced its interim results for the six months ended June 2026, with revenue of RMB 1.007 billion, up 21% year-on-year, and net profit of RMB 80.08 million, down 34.3%.10d ago

On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.16d ago

Similar companies

Genor Biopharma Holdings Limited06998.HK SELLAS Life Sciences Group, Inc.SLS Soleno Therapeutics, Inc.SLNO BioDlink International Company Limited01875.HK Nurix Therapeutics, Inc.NRIX 寿仙谷603896.SH Find similar companies →

Latest newsMore news →

Viva Biotech Holdings announced its interim results for the six months ended June 2026, with revenue of RMB 1.007 billion, up 21% year-on-year, and net profit of RMB 80.08 million, down 34.3%.10d ago On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.16d ago